Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.53 |
| ▸ | PTGES | O14684 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL316291 | 0.81 | SGMS2 (0.53) | LMNAALDH1A1 | |
| SCHEMBL6492975 | 0.80 | LRRK2 (0.60) | LRRK2POLBLMNAUSP2CCR5 | |
| SCHEMBL8337852 | 0.79 | PTGES (0.59) | LRRK2PTGESCCR5FOLH1 | |
| SCHEMBL5431545 | 0.77 | LRRK2 (0.63) | LRRK2POLBLMNAUSP2CCR5 | |
| SCHEMBL384896 | 0.75 | FOLH1 (0.68) | LRRK2PTGESPOLBLMNAFOLH1 | |
| SCHEMBL547302 | 0.75 | CCR5 (0.54) | LRRK2PTGESLMNAUSP2CCR5 | |
| SCHEMBL1646591 | 0.75 | LRRK2 (0.61) | LRRK2POLBCCR5FOLH1 | |
| SCHEMBL30591972 | 0.74 | PTGDR2 (0.67) | LRRK2POLBLMNAUSP2FOLH1 | |
| SCHEMBL6452235 | 0.74 | PTGDR2 (0.67) | LRRK2POLBLMNAUSP2FOLH1 | |
| SCHEMBL5927404 | 0.73 | ABCG2 (0.59) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110601-B2 | Compound, α1 adrenergic receptor antagonistic agent, and composition | SUNTORY HOLDINGS LIMITED (JP) | 2012-02-07 | — | — | US | disclosed |
| US-8110601-B2 | Compound, α1 adrenergic receptor antagonistic agent, and composition | SUNTORY HOLDINGS LIMITED (JP) | 2012-02-07 | — | — | US | disclosed |
| US-20100004328-A1 | COMPOUND, Alpha1 ADRENERGIC RECEPTOR ANTAGONISTIC AGENT, AND COMPOSITION | SUNTORY HOLDING LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004328-A1 | COMPOUND, Alpha1 ADRENERGIC RECEPTOR ANTAGONISTIC AGENT, AND COMPOSITION | SUNTORY HOLDING LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2128148-A1 | COMPOUND, ALPHA 1 ADRENALINE RECEPTOR ANTAGONIST, AND COMPOSITION | Suntory Holdings Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
| JP-2008189554-A | METHOD FOR SYNTHESIZING BENZOFURANCARBOXAMIDE DERIVATIVE | SUNTORY LTD | 2008-08-21 | — | — | JP | disclosed |
| US-7385064-B1 | Catalysts for use in enantioselective synthesis | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2008-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004328-A1 | COMPOUND, Alpha1 ADRENERGIC RECEPTOR ANTAGONISTIC AGENT, AND COMPOSITION | ADRB1, ADRA1A, ADRA1D | LRRK2 997/4885PTGES 1735/4885POLB 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.